NASDAQ:COGT Cogent Biosciences (COGT) Stock Price, News & Analysis → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free COGT Stock Alerts $6.02 +0.01 (+0.17%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$5.95▼$6.1650-Day Range$5.78▼$9.0252-Week Range$3.67▼$13.50Volume912,165 shsAverage Volume1.24 million shsMarket Capitalization$575.57 millionP/E RatioN/ADividend YieldN/APrice Target$13.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Cogent Biosciences alerts: Email Address Cogent Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside127.0% Upside$13.67 Price TargetShort InterestBearish13.04% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.14Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.89) to ($1.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.54 out of 5 starsMedical Sector682nd out of 914 stocksPharmaceutical Preparations Industry309th out of 418 stocks 4.4 Analyst's Opinion Consensus RatingCogent Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCogent Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.04% of the outstanding shares of Cogent Biosciences have been sold short.Short Interest Ratio / Days to CoverCogent Biosciences has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Cogent Biosciences has recently increased by 15.04%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCogent Biosciences does not currently pay a dividend.Dividend GrowthCogent Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for COGT. Previous Next 1.0 News and Social Media Coverage News SentimentCogent Biosciences has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cogent Biosciences this week, compared to 2 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cogent Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.10% of the stock of Cogent Biosciences is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cogent Biosciences are expected to grow in the coming year, from ($1.89) to ($1.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cogent Biosciences is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cogent Biosciences is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCogent Biosciences has a P/B Ratio of 2.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Cogent Biosciences Stock (NASDAQ:COGT)Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Read More COGT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COGT Stock News HeadlinesApril 18, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)April 9, 2024 | globenewswire.comCogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 InhibitorApril 27, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… March 16, 2024 | finance.yahoo.comCOGT Apr 2024 7.500 callMarch 14, 2024 | insidermonkey.com5 Best Biotech Stocks To Buy Under $20February 28, 2024 | finance.yahoo.comCOGT Reports Full Year 2023 Financial Results and Business HighlightsFebruary 27, 2024 | msn.comBaird Downgrades Cogent Biosciences (COGT)February 26, 2024 | msn.comCogent Biosciences GAAP EPS of -$0.63April 27, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… February 26, 2024 | globenewswire.comCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsFebruary 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cogent Biosciences as Bezuclastinib Showcases Strong Market PotentialFebruary 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Lantheus (LNTH) and Ardelyx (ARDX)February 22, 2024 | msn.comCogent Biosciences stock jumps on Phase 2 data for bezuclastinibFebruary 22, 2024 | globenewswire.comCogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic MastocytosisFebruary 22, 2024 | markets.businessinsider.comBuy Rating Affirmed on Cogent Biosciences Amid Positive Outlook for Bezuclastinib’s Efficacy and SafetyFebruary 15, 2024 | finance.yahoo.comSteven Cohen's Point72 Asset Management Bolsters Position in Cogent BiosciencesFebruary 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Elevance Health (ELV) and Cogent Biosciences (COGT)February 14, 2024 | seekingalpha.comCogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data CatalystFebruary 14, 2024 | finance.yahoo.comCogent Biosciences Announces Oversubscribed $225 Million Private PlacementFebruary 14, 2024 | globenewswire.comCogent Biosciences Announces Oversubscribed $225 Million Private PlacementFebruary 5, 2024 | finance.yahoo.comCogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual MeetingJanuary 9, 2024 | msn.comCogent Biosciences issues study updates on bezuclastinib, CGT4859January 9, 2024 | finance.yahoo.comCogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted TherapeuticsJanuary 2, 2024 | finance.yahoo.comCogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 22, 2023 | benzinga.comCogent Biosciences Stock (NASDAQ:COGT) Dividends: History, Yield and DatesDecember 12, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Cogent Biosciences (COGT), Syndax Pharmaceuticals (SNDX)December 11, 2023 | realmoney.thestreet.comWedbush downgrades Cogent Biosciences to Neutral, cuts price target to $5See More Headlines Receive COGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/26/2024Today4/27/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:COGT CUSIPN/A CIK1460329 Webwww.cogint.com Phone(617) 945-5576FaxN/AEmployees164Year FoundedN/APrice Target and Rating Average Stock Price Target$13.67 High Stock Price Target$20.00 Low Stock Price Target$8.00 Potential Upside/Downside+127.0%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-192,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-86.67% Return on Assets-58.11% Debt Debt-to-Equity RatioN/A Current Ratio7.09 Quick Ratio7.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.30 per share Price / Book2.62Miscellaneous Outstanding Shares95,610,000Free Float90,737,000Market Cap$575.57 million OptionableOptionable Beta1.50 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Andrew R. Robbins M.B.A. (Age 48)President, CEO & Director Comp: $1.06MDr. John Edward Robinson Ph.D. (Age 49)Chief Scientific Officer Comp: $749.89kDr. Jessica Sachs M.D. (Age 49)Chief Medical Officer Comp: $773.92kMr. John L. Green C.A. (Age 44)CPA, CFO & Principal Accounting Officer Comp: $763.99kMr. Brad BarnettChief Technology OfficerChristi WaarichSenior Director of Investor RelationsMr. Evan D. Kearns J.D. (Age 44)Chief Legal Officer & Corporate Secretary Ms. Erin SchellhammerChief People OfficerMr. Dana R. Martin Pharm.D.Senior Vice President of Medical AffairsBrad FellSenior Vice President of ChemistryMore ExecutivesKey CompetitorsY-mAbs TherapeuticsNASDAQ:YMABSilence TherapeuticsNASDAQ:SLNEvolusNASDAQ:EOLSDisc MedicineNASDAQ:IRONBicycle TherapeuticsNASDAQ:BCYCView All CompetitorsInsiders & InstitutionsFisher Asset Management LLCBought 33,222 shares on 3/5/2024Ownership: 0.098%Perceptive Advisors LLCSold 1,186,512 shares on 2/26/2024Ownership: 1.304%Sierra Summit Advisors LLCBought 56,231 shares on 2/22/2024Ownership: 0.065%Eventide Asset Management LLCBought 82,968 shares on 2/20/2024Ownership: 2.593%Forefront Analytics LLCBought 19,982 shares on 2/15/2024Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions COGT Stock Analysis - Frequently Asked Questions Should I buy or sell Cogent Biosciences stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cogent Biosciences in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" COGT shares. View COGT analyst ratings or view top-rated stocks. What is Cogent Biosciences' stock price target for 2024? 7 Wall Street research analysts have issued 1-year price targets for Cogent Biosciences' stock. Their COGT share price targets range from $8.00 to $20.00. On average, they anticipate the company's stock price to reach $13.67 in the next year. This suggests a possible upside of 127.0% from the stock's current price. View analysts price targets for COGT or view top-rated stocks among Wall Street analysts. How have COGT shares performed in 2024? Cogent Biosciences' stock was trading at $5.88 at the start of the year. Since then, COGT shares have increased by 2.4% and is now trading at $6.02. View the best growth stocks for 2024 here. Are investors shorting Cogent Biosciences? Cogent Biosciences saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 12,470,000 shares, an increase of 15.0% from the March 31st total of 10,840,000 shares. Based on an average trading volume of 2,100,000 shares, the short-interest ratio is currently 5.9 days. View Cogent Biosciences' Short Interest. When is Cogent Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our COGT earnings forecast. How were Cogent Biosciences' earnings last quarter? Cogent Biosciences, Inc. (NASDAQ:COGT) posted its earnings results on Monday, February, 26th. The technology company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.55) by $0.08. What ETFs hold Cogent Biosciences' stock? ETFs with the largest weight of Cogent Biosciences (NASDAQ:COGT) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).Tema Oncology ETF (CANC). What other stocks do shareholders of Cogent Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Viveve Medical (VIVE), Red Violet (RDVT), Freeport-McMoRan (FCX), HP (HPQ), Nutanix (NTNX), OPKO Health (OPK), STMicroelectronics (STM) and Actinium Pharmaceuticals (ATNM). How do I buy shares of Cogent Biosciences? Shares of COGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:COGT) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace4 Cryptos BETTER than BitcoinTrue Market InsidersThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.